EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

Abstract Both EZH2 and its homolog EZH1 function as histone H3 Lysine 27 (H3K27) methyltransferases and repress the transcription of target genes. Dysregulation of H3K27 trimethylation (H3K27me3) plays an important role in the development and progression of cancers such as hepatocellular carcinoma (...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuko Kusakabe, Tetsuhiro Chiba, Motohiko Oshima, Shuhei Koide, Ola Rizq, Kazumasa Aoyama, Junjie Ao, Tatsuya Kaneko, Hiroaki Kanzaki, Kengo Kanayama, Takahiro Maeda, Tomoko Saito, Ryo Nakagawa, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Sadahisa Ogasawara, Eiichiro Suzuki, Shingo Nakamoto, Shin Yasui, Rintaro Mikata, Ryosuke Muroyama, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Naoya Mimura, Anqi Ma, Jian Jin, Yoh Zen, Masayuki Otsuka, Atsushi Kaneda, Atsushi Iwama, Naoya Kato
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8eb58697caf4466e8a01b8253f2d212f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

Ejemplares similares